---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000005"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:23:37.270009+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022

## Summary
- Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.
- EPS loss $0.14 basic/diluted versus EPS profit $0.59 basic/0.54 diluted a year ago.
- Partnered program starts reached 101 cumulative (up 20% YoY); 9 molecules in clinic (up from 6).
- R&D spending rose to $52.6M from $26.4M; cash and marketable securities $821.5M.
- Management highlighted T-cell engager platform progress; no guidance provided.

## SEC filing metadata
- accession: 0001703057-23-000005
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/0001703057-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/abcl-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000005
- JSON: https://secwatch.observer/filing/0001703057-23-000005.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.